Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Dru... (in all of thesepatients Dr. Borchmann c...)

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

Date:11/14/2007

in all of these patients," Dr. Borchmann commented. Anthracyclines are an established cornerstone treatment and potentially curative in breast cancer, acute leukemia, and lymphoma therapy, however anthracyclines cause cumulative acute and chronic irreversible damage to the heart muscle.

XYOTAX(TM) (paclitaxel poliglumex, CT-2103)

A founding member of the British Thoracic Oncology Group (BTOG) and Clinical Director of the HOPE Directorate at St. James' Hospital, Kenneth J. O'Byrne, M.D., presented the phase III results of XYOTAX in first-line treatment of non-small cell lung cancer noting that "equivalent survival to gemcitabine or vinorelbine in poor performance status patients and the reduction in toxicity coupled with the convenience of administration is very important and it's on the basis of this that positive advice has been received from the EMEA in Europe." Dr. O'Byrne also presented data suggesting that XYOTAX may be particularly effective in women with pre-menopausal estradiol levels where survival appears better than in similar patients treated with conventional chemotherapy.

Brostallicin

Brostallicin has been studied in combination with classic anti-cancer agents and with new molecularly targeted agents in more than 200 patients in phase I and II clinical trials. In addition to its unique mechanism of action as a minor groove binder, brostallicin has a good safety profile with no cumulative marrow toxicities to-date. Dr. Von Hoff said, "It meant a lot to us to have the EORTC set up a randomized phase II trial comparing brostallicin to doxorubicin, which is the standard treatment, because it demonstrates a level of confidence in the drug. Utilizing genomic screening for a tumor's context of vulnerability has helped design and guide ongoing and planned phase II trials of brostallicin."

James A. Bianco, M.D., CTI's President and CEO summarized the day's presentations by highlighting the near-term regulatory milestones for CTI's
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials

Post Your Comments:

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Dru...(in all of thesepatients Dr. Borchmann c...),Health